FOLH1 and metastatic neoplasm: In this population of prostatectomy patients with or without PORT, rates of local recurrence ranged from 18.5 to 31% depending on PSA at the time of 18F-PSMA-1007 PET/CT, with an increase in rates of nodal and metastatic disease with increased PSA [15].